Definium Therapeutics (NASDAQ:DFTX) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Definium Therapeutics (NASDAQ:DFTX) issued its quarterly earnings results on Thursday. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02), FiscalAI reports.

Here are the key takeaways from Definium Therapeutics’ conference call:

• Upcoming catalysts: Company expects three Phase 3 readouts in 2026 with Emerge (MDD) top-line in late Q2 2026, Voyage (GAD) in early Q3, and Panorama in H2 — plus Ascend dosing beginning in early Q2.
• Voyage completed a blinded sample-size re-estimation with no increase required; observed lower variability (SD ~6.7 vs planned 10) and lower non-evaluable rate, implying substantially higher power to detect the prespecified treatment effect.
• Strong balance sheet: year-end cash, equivalents and investments of $411.6M, which management says should fund operations into 2028 and supports pre-commercial investments and launch prep.
• Pipeline diversification: First participant dosed in Phase 2a of DT-402 (R‑MDMA) for autism spectrum disorder with initial data expected later in 2026, adding an earlier-stage program beyond DT120 ODT.
• Rising burn and loss: 2025 net loss widened to $183.8M (from $108.7M) driven by higher R&D and G&A spend, reflecting accelerated development and commercialization spending.

Definium Therapeutics Price Performance

NASDAQ DFTX traded down $0.33 on Thursday, reaching $17.29. The company had a trading volume of 1,123,415 shares, compared to its average volume of 1,291,239. The company has a current ratio of 3.30, a quick ratio of 3.30 and a debt-to-equity ratio of 0.31. The company’s fifty day moving average is $15.47 and its 200 day moving average is $12.72. Definium Therapeutics has a 52-week low of $4.70 and a 52-week high of $18.70.

Insider Transactions at Definium Therapeutics

In other news, insider Mark Sullivan sold 11,276 shares of the stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $148,279.40. Following the completion of the sale, the insider owned 282,576 shares in the company, valued at $3,715,874.40. This represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Robert Barrow sold 25,791 shares of the business’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $339,151.65. Following the transaction, the chief executive officer owned 778,477 shares in the company, valued at approximately $10,236,972.55. This trade represents a 3.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 42,667 shares of company stock worth $561,071 in the last quarter. 2.26% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Definium Therapeutics

Several institutional investors have recently modified their holdings of the business. Cerity Partners LLC increased its position in shares of Definium Therapeutics by 2.4% during the second quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock valued at $322,000 after acquiring an additional 1,165 shares during the last quarter. Creative Planning increased its position in shares of Definium Therapeutics by 2.6% during the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after purchasing an additional 1,655 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares during the period. Mercer Global Advisors Inc. ADV boosted its holdings in shares of Definium Therapeutics by 10.5% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock worth $259,000 after buying an additional 2,079 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Definium Therapeutics by 5.1% during the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock valued at $315,000 after buying an additional 2,342 shares during the period. 27.91% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

DFTX has been the topic of several research analyst reports. Robert W. Baird set a $37.00 target price on Definium Therapeutics in a research report on Thursday, January 29th. Jefferies Financial Group initiated coverage on Definium Therapeutics in a research note on Thursday, January 29th. They issued a “buy” rating and a $30.00 price target on the stock. Wolfe Research began coverage on shares of Definium Therapeutics in a research report on Monday. They set an “outperform” rating and a $25.00 price objective for the company. Canaccord Genuity Group increased their target price on shares of Definium Therapeutics from $16.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Definium Therapeutics in a research note on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $34.20.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.